# Schedules of Controlled Substances: Placement of 2-Methyl AP-237 in Schedule I > **Author:** Benjamin Caplan, MD (ABFM Board Certified, MA Lic. #240562, NPI: 1962722637) > **Publisher:** CED Clinic (https://cedclinic.com) > **Canonical URL:** https://cedclinic.com/synthetic-opioid-scheduling-2-methyl-ap-237-schedule-i/ > **Published:** 2026-03-10T11:17:04-04:00 | **Last Modified / Clinically Audited:** 2026-09-28T17:09:35-04:00 > **Clinical Summary:** Learn about synthetic opioid scheduling with 2-Methyl AP-237 placed in Schedule I by the DEA for high abuse potential and no accepted medical use. --- ✦ New CED Clinical Relevance #70 Notable Clinical Interest Emerging findings or policy developments worth monitoring closely. ⚒ Policy Watch  |  Regulations.gov PolicySafetyResearch Clinical Summary The Drug Enforcement Administration has placed 2-methyl AP-237, a synthetic opioid analog, into Schedule I of the [Controlled Substances](https://cedclinic.com/dea-scheduling-cannabis-policy-march-15-2026/) Act due to its high abuse potential and lack of accepted medical use. This regulatory action reflects ongoing federal efforts to address emerging synthetic drugs that pose [public health](https://cedclinic.com/cannabis-mold-contamination-risks-recall-safety/) risks through rapid scheduling mechanisms. While this particular compound is not cannabis-related, the scheduling precedent demonstrates how the DEA uses emergency scheduling authority to control novel psychoactive substances before they become widespread [public health](https://cedclinic.com/cannabis-mold-contamination-risks-recall-safety/) threats. Clinicians should be aware that similar scheduling actions may affect cannabis-derived or cannabis-adjacent compounds, particularly as novel cannabinoids and synthetic analogs continue to emerge in unregulated markets. The rapid regulatory response to new synthetic opioids underscores the need for clinical vigilance regarding substance misuse patterns and emerging drug trends in patient populations. Clinicians should stay informed about DEA scheduling updates and educate patients about the risks of unregulated synthetic substances while maintaining evidence-based approaches to [pain management](https://cedclinic.com/cbd-cbg-topicals-for-eczema/) and substance use disorder treatment. Clinical Perspective The DEA’s emergency scheduling of 2-methyl AP-237, a novel synthetic opioid, reflects the ongoing challenge of designer drug proliferation outpacing regulatory frameworks and highlights a gap that clinicians should monitor. While emergency scheduling aims to limit availability and harm, it does not directly change [clinical practice](https://cedclinic.com/cannabis-reproductive-health-women-clinical-evidence/) for most providers since these compounds are not prescribed therapeutically and appear primarily in illicit markets. However, clinicians should remain aware that novel synthetic opioids increasingly appear in unregulated drug supplies and may contribute to overdose cases in which standard toxicology screening fails to identify the specific agent, complicating clinical management and [harm reduction](https://cedclinic.com/can-you-mix-weed-and-alcohol/) counseling. The scheduling action underscores the importance of obtaining detailed substance use histories and considering novel synthetic opioid exposure in patients presenting with unexplained opioid toxidrome or overdose unresponsive to naloxone. Practically, providers caring for patients with opioid use 💬 Join the Conversation Have a question about how this applies to your situation? [Ask Dr. Caplan →](https://benjamincaplan.com/ask-dr-caplan) Want to discuss this topic with other patients and caregivers? [Join the forum discussion →](https://cedclinic.com/interact/discussion-forums/forum/cannabis-industry/) Have thoughts on this? Share it: [𝕏 Share on X](https://twitter.com/intent/tweet?text=Just+read+this+on+CEDclinic.com%3A+Schedules+of+Controlled+Substances%3A+Placement+of+2-Methyl+AP-237+in+Schedule+I+%40drcaplan&url=https%3A%2F%2Fwww.regulations.gov%2Fdocument%2FDEA-2024-0026-0001) [in Share on LinkedIn](https://www.linkedin.com/sharing/share-offsite/?url=https%3A%2F%2Fwww.regulations.gov%2Fdocument%2FDEA-2024-0026-0001) [🦅 Share on BlueSky](https://bsky.app/intent/compose?text=Just+read+this%3A+Schedules+of+Controlled+Substances%3A+Placement+of+2-Methyl+AP-237+in+Schedule+I+--+via+%40drcaplan.bsky.social+https%3A%2F%2Fwww.regulations.gov%2Fdocument%2FDEA-2024-0026-0001) [📷 Follow on Instagram](https://www.instagram.com/drbenjamincaplan/) [📝 Read more on Substack](https://substack.com/@doctorapproved) [🔔 Subscribe via RSS](https://cedclinic.com/category/cannabis-news/feed/) Related Articles - [Daily Digest: Last 9 Hours: Stroke Risk From Recreational Drugs and DEA Scheduling Actions — March 08, 2026](https://cedclinic.com/daily-digest-last-9-hours-stroke-risk-from-recreational-drugs-and-dea-scheduling-actions-march-08-2026/) - [Firefighters are a step closer to being able to use medical cannabis – WMAR](https://cedclinic.com/medical-cannabis-firefighters-access-update/) - [Cannabis compounds CBD and CBG may help reverse fatty liver disease, study finds](https://cedclinic.com/cbd-cbg-fatty-liver-disease-research/) 📰 Source: [https://www.regulations.gov/document/DEA-2024-0026-0001](https://www.regulations.gov/document/DEA-2024-0026-0001) Further Reading CED Clinic Blog[Cannabis-Infused Beverages as Alcohol Alternatives: New York at Five Years](https://cedclinic.com/cannabis-beverage-substitution-alcohol-new-york-five-years/) Research Digest[Daily Digest 2026-03-07](https://cedclinic.com/adolescent-cannabis-psychiatric-outcomes-2026-digest/) Evidence Watch[`Cannabinoid Clinical Trials: CBD Cortical Excitability Study`](https://cedclinic.com/cannabidiol-lacks-intrinsic-anti-epileptic-properties-trial/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) Physician-Led, Whole-Person Care A doctor who takes the time to truly understand you. Personal care that starts with listening and is guided by experience and ingenuity. Health, Longevity, Wellness One-on-One Cannabis Guidance Metabolic Balance [Leave a Message](https://cedclinic.com/contact/) [Metabolic Care](https://cedclinic.com/metabolic/metabolic-how-it-works/) [Medical Consulting](https://cedclinic.com/book/) [Cannabis Care](https://cedclinic.com/book/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) RELATED READING AT CED CLINIC Continue exploring the evidence [Schedules of Controlled Substances: Placement of Etodesnitazene, N-Pyrrolidino etonitazene, and Protonitazene in Schedule I](https://cedclinic.com/schedules-controlled-substances-placement-schedule-i/) Explore the DEA's scheduling of other synthetic opioids similar to 2-Methyl AP-237 and their regulatory impact. [Read More](https://cedclinic.com/schedules-controlled-substances-placement-schedule-i/) [Schedules of Controlled Substances: Placement of Butonitazene, Flunitazene, and Metodesnitazene in Schedule I](https://cedclinic.com/synthetic-opioids-schedule-i-placement-butonitazene-flunitazene/) Detailed review of recent Schedule I placements of synthetic opioids and their clinical relevance. [Learn More](https://cedclinic.com/synthetic-opioids-schedule-i-placement-butonitazene-flunitazene/) [Schedules of Controlled Substances: Placement of 3-Methoxyphencyclidine in Schedule I](https://cedclinic.com/dea-drug-scheduling-updates-3-methoxyphencyclidine-schedule-i/) Insight into the scheduling of novel psychoactive substances and their implications for healthcare providers. [Explore Article](https://cedclinic.com/dea-drug-scheduling-updates-3-methoxyphencyclidine-schedule-i/) ### Related --- ### Verification & Medical Governance - **Lead Clinical Author:** Benjamin Caplan, MD - **Credentials:** Board Certified in Family Medicine (ABFM), Founder & CMO CED Clinic & CED Foundation, Author of *The Doctor-Approved Cannabis Handbook* (Penguin Random House). - **Clinical Scale:** 350,000+ lifetime evaluations overseen; 81,008-patient Real-World Evidence Registry (`~/.ced_rwe_vault.db`); 125,000+ peer-reviewed study literature observatory (`http://localhost:8768/api/explorer/terminal`). - **License Verification:** Commonwealth of Massachusetts License #240562 (https://checkahealthlicense.mass.gov/). - **NPI Registry:** 1962722637 (https://npiregistry.cms.hhs.gov/provider-view/1962722637). - **Ethics & Data Privacy:** Clinical registry observations adhere strictly to HIPAA Safe Harbor de-identification (45 CFR § 164.514(b)) and criteria for secondary research exemption under 45 CFR § 46.104(d)(4).